CINV Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cINV treatment market size is expected to grow from USD 5.38 billion in 2025 to USD 5.68 billion in 2026 and is forecast to reach USD 7.46 billion by 2031 at 5.62% CAGR over 2026-2031. This report is Segmented by Drug Class (5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Dopamine Antagonists, Cannabinoid Antagonists, and More), Formulation (Oral, Injectable, Transdermal, Sublingual), End User (Hospitals, Oncology & Specialty Clinics, Homecare Settings & ASCs), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global CINV Treatment Market Trends and Insights

Increasing Prevalence of Cancer

Breakthrough oncology drugs cleared by the FDA in 2024 widened the treated patient pool, intensifying demand for supportive care antiemetics. Longer survival times among older populations further lengthen exposure to chemotherapy and related nausea risks, ensuring that antiemetic use scales alongside oncology advances. The demographic shift toward aging populations in developed markets compounds this trend, as older patients typically require more aggressive chemotherapy protocols with higher emetogenic potential. Additionally, improved cancer screening programs detect malignancies at earlier stages, leading to longer treatment durations and cumulative antiemetic exposure per patient.

Adoption of Highly-Emetogenic Chemotherapy Regimens

Clinical protocols incorporating anthracycline-based or platinum-dense regimens hinge on robust antiemetic prophylaxis, steering prescribers toward premium NK1 antagonists. A study showed 94.7% complete response when olanzapine, palonosetron, and fosaprepitant were combined for high-risk patients.The trend accelerates as precision oncology identifies patient subgroups requiring intensified treatment approaches, creating sustained demand for advanced antiemetic solutions. Furthermore, the integration of immunotherapy with traditional chemotherapy creates novel emetogenic profiles that require specialized management strategies.

Patent Expiries Driving Price Erosion

Loss of exclusivity for brands such as Sancuso intensifies generic entry, compressing average selling prices and challenging R&D reinvestment models for incumbents, particularly in regions where payers prioritize least-cost alternatives. Companies respond through defensive strategies including authorized generics, value-based contracting, and lifecycle management initiatives, but these approaches typically delay rather than prevent revenue erosion. The pricing pressure intensifies in emerging markets where healthcare systems prioritize cost-effectiveness over brand preference, accelerating generic adoption rates.

Other drivers and restraints analyzed in the detailed report include:

• Guideline-Driven Uptake of Triple Antiemetic Therapy
• Fixed-Dose Combos & Extended-Release Formulations
• Side-Effect Profile Limiting Adherence

Segment Analysis

5-HT3 receptor antagonists retained a 44.12% CINV treatment market share in 2025, a position built on long-standing clinical familiarity. Yet the segment grows modestly as clinicians increasingly adopt NK1 agents for delayed-phase protection. The CINV treatment market size tied to NK1 antagonists is on track to rise at 6.42% CAGR thanks to guideline endorsements and new once-daily formulations. Robust clinical evidence underpins NK1 uptake, and brands such as CINVANTI extend protection through 2035 patents, giving innovators pricing latitude.

Complementary roles for dopamine antagonists and corticosteroids persist, while cannabinoids remain a niche option for refractory cases. Evidence supporting olanzapine’s multi-receptor blockade is altering rescue therapy preferences, especially for breakthrough nausea where single-mechanism drugs show gaps. As combination regimens become standard, manufacturers that integrate NK1 components with 5-HT3 or corticosteroids in a single capsule or infusion capture workflow efficiencies that resonate with oncology clinics.

Complete Report Scope:

• By Drug Class
  • 5-HT3 Receptor Antagonists
  • NK1 Receptor Antagonists
  • Dopamine Antagonists
  • Cannabinoid Antagonists
  • Corticosteroids
  • Other Classes (Benzodiazepines, Antihistamines)
• By Formulation
  • Oral
  • Injectable
  • Transdermal
  • Sublingual
• By End User
  • Hospitals
  • Oncology & Specialty Clinics
  • Homecare Settings & ASCs
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 37.20% of global revenue in 2025 owing to established clinical guideline enforcement, rapid FDA approvals, and extensive insurance coverage for supportive oncology drugs. The region’s clinicians readily adopt extended-release innovations despite higher acquisition costs when data show reduced rescue medication use. Patent expiries are expected to temper annual price growth, but volume expansion from rising cancer incidence and broader use of immuno-chemotherapy combinations sustains overall market value. Value-based care models are nudging hospital systems toward longer-acting antiemetics that cut infusion chair occupancy and readmissions.

Asia-Pacific is projected to grow at 6.78% CAGR through 2031 as China, India, and Southeast Asian countries expand oncology infrastructure and harmonize regulatory pathways. China’s National Medical Products Administration cleared 228 NDAs in 2024, 37% for antineoplastic agents, catalyzing supportive-care demand. Domestic manufacturers introduce cost-competitive NK1 generics, while multinational firms leverage accelerated pathways to launch fixed-dose combos. Pharmacovigilance capacity is rising, making data-driven formulary inclusion more feasible across public hospitals.

Europe maintains consistent demand anchored by harmonized EMA approvals and robust health technology assessments that balance innovation with cost containment. National reimbursement boards emphasize real-world effectiveness data, favoring products that document reduced rescue therapy and hospital re-visits. Emerging regions in MEA and South America remain nascent contributors yet represent strategic expansions for companies willing to localize production and navigate fragmented regulatory landscapes.

List of Companies Covered in this Report:

• Merck
• GlaxoSmithKline
• Heron Therapeutics
• Helsinn Group
• Novartis
• Pfizer
• Johnson & Johnson
• Baxter
• Teva Pharmaceutical Industries
• Sun Pharma Industries Ltd.
• Roche
• Dr Reddy’s Laboratories
• Cipla
• Eisai
• Accord Healthcare
• Mundipharma Intl.
• Tesaro (Biotech)
• Fresenius
• Lupin
• Orchid Healthcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support